Sustained Virologic Response
"Sustained Virologic Response" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The continuous, long-term suppression of VIRAL LOAD, generally to undetectable levels, as the result of treatment with ANTIVIRAL AGENTS.
| Descriptor ID |
D000072230
|
| MeSH Number(s) |
E01.789.800.570 N04.761.559.590.800.665 N05.715.360.575.575.800.665
|
| Concept/Terms |
Sustained Virologic Response- Sustained Virologic Response
- Response, Sustained Virologic
- Sustained Virologic Responses
- Virologic Response, Sustained
- Sustained Viral Suppression
- Suppression, Sustained Viral
- Sustained Viral Suppressions
|
Below are MeSH descriptors whose meaning is more general than "Sustained Virologic Response".
Below are MeSH descriptors whose meaning is more specific than "Sustained Virologic Response".
This graph shows the total number of publications written about "Sustained Virologic Response" by people in this website by year, and whether "Sustained Virologic Response" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sustained Virologic Response" by people in Profiles.
-
Linkage to specialty care in the hepatitis C care cascade. J Investig Med. 2021 02; 69(2):324-332.
-
Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. Aliment Pharmacol Ther. 2020 02; 51(3):364-373.
-
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology. 2019 12; 157(6):1506-1517.e1.
-
Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat. 2019 03; 26(3):323-328.
-
Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral Res. 2017 08; 144:281-285.
-
Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2016 Feb; 36(2):203-17.
-
Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat. 2016 07; 23(7):496-505.